Metformin Canon, 1000 mg 60 pcs

Metformin inhibits gluconeogenesis in liver, decreases glucose absorption from intestine, increases peripheral glucose utilization, and increases tissue sensitivity to insulin. At the same time it has no effect on insulin secretion by beta-cells of the pancreas and does not cause hypoglycemic reactions.

Limits triglycerides and low-density linoproteins in the blood. Stabilizes or reduces body weight. Has a fibrinolytic effect by inhibiting tissue-type plasminogen activator inhibitor.

Pharmacokinetics .

Indications

Type 2 diabetes without predisposition to ketoacidosis (especially in obese patients) when diet therapy is ineffective; in combination with insulin, in type 2 diabetes, especially with a pronounced degree of obesity accompanied by secondary insulin resistance.

Active ingredient

Composition

Active ingredients:

metformin 500 mg

Auxiliary substances:

povidone K 90;

corn starch;

crosspovidone;

magnesium stearate;

talc

Composition of the shell:

Methacrylic acid and methyl methacrylate copolymer (eudragit L 100-55); macrogol 6000; titanium dioxide; talc

How to take, the dosage

The dose of the drug is set by the doctor individually, depending on the level of glucose in the blood.

The initial dose is 500-1000 mg per day (1-2 tablets). After 10-15 days further gradual increase of the dose depending on blood glucose level is possible.

The maintenance dose of the drug is usually 1500-2000 mg per day. (3-4 tablets) The maximum dose is 3000 mg per day (6 tablets).

In elderly patients, the recommended daily dose should not exceed 1 g (2 tablets).

The tablets Metformin should be taken whole during or immediately after a meal, with a small amount of liquid (glass of water). To reduce gastrointestinal side effects, the daily dose should be divided into 2 to 3 doses.

Because of the increased risk of lactoacidosis, the drug dose should be reduced if there are severe metabolic disorders.

Interaction

The concomitant administration of danazol is not recommended to avoid the hyperglycemic effects of the latter. If treatment with danazolol is necessary and after discontinuation of the latter, metformin dose should be adjusted and glycemic levels monitored.

Combinations requiring special caution: Chlorpromazine – when taken in high doses (100 mg/day) increases glycemia by reducing insulin release.

When treated with neuroleptics and after discontinuation of the latter, metformin dose adjustment is required with glycemic control.

Concomitant use with sulfonylurea derivatives, acarbose, insulin, NSAIDs, MAO inhibitors, oxytetracycline, ACE inhibitors, clofibrate derivatives, cyclophosphamide, β-adrenoblockers may increase the hypoglycemic effect of metformin.

Concomitant use with GCS, oral contraceptives, epinephrine, sympathomimetics, glucagon, thyroid hormones, thiazide and loop diuretics, phenothiazine derivatives, nicotinic acid derivatives may decrease the hypoglycemic effect of metformin.

Cimetidine slows metformin excretion, which increases the risk of lactacidosis.

Metformin may decrease the effect of anticoagulants (coumarin derivatives).

Alcohol intake increases the risk of lactacidosis during acute alcohol intoxication, especially in cases of starvation or compliance with a low-fat diet, as well as in liver failure.

Special Instructions

Key kidney function should be monitored during treatment. Plasma lactate should be determined at least twice a year, as well as in case of myalgia. In addition, serum creatinine level should be controlled once every 6 months (especially in elderly patients). Metformin should not be prescribed if blood creatinine level is higher than 135 μmol/l in men and 110 μmol/l in women.

Metformin may be used in combination with sulfonylurea derivatives. In this case, particularly careful monitoring of blood glucose levels is necessary.

For 48 hours before and for 48 hours after X-ray contrast (urography, IV angiography), Metformin should be discontinued.

If a patient has a bronchopulmonary infection or a urinary tract infection, the attending physician should be informed immediately.

Alcohol and medications containing ethanol should be avoided during treatment.

Impact on driving and operating machinery

The use of the drug in monotherapy does not affect the ability to drive and operate machinery.

When combining Metformin with other hypoglycemic agents (sulfonylurea derivatives, insulin) hypoglycemic states may occur, which impair the ability to drive vehicles and to engage in other potentially dangerous activities requiring increased attention and quick psychomotor reactions.

Contraindications

The drug is not recommended for persons older than 60 years of age who perform heavy physical work, due to the increased risk of lactic acidosis in them.

Side effects

Gastrointestinal system disorders: nausea, vomiting, metallic taste in the mouth, lack of appetite, diarrhea, flatulence, abdominal pain. These symptoms are especially common at the beginning of treatment and usually go away on their own. These symptoms may be reduced by administration of antacids, atropine derivatives, or antispasmodics.

Metabolic disorders: in rare cases – lactacidosis (requires discontinuation of treatment); with long-term treatment – hypovitaminosis B12 (malabsorption).

Hematopoietic organs: in rare cases – megaloblastic anemia.

Endocrine system: hypoglycemia.

Allergic reactions: skin rash.

Overdose

In case of overdose of Metformin drug, lactacidosis with fatal outcome is possible. The cause of lactacidosis may also be cumulation of the drug due to renal dysfunction.

The symptoms of lactacidosis: nausea, vomiting, diarrhea, decreased body temperature, abdominal pain, muscle pain; rapid breathing, dizziness, loss of consciousness and coma may occur.

Treatment: if signs of lactacidosis occur, treatment with Metformin should be stopped immediately, the patient should be immediately hospitalized and the lactate concentration determined to confirm the diagnosis. The most effective measure of lactate and metformin elimination from the body is hemodialysis. Symptomatic treatment is also carried out.

When combined therapy with sulfonylurea preparations with Metformin may lead to hypoglycemia.

Pregnancy use

If pregnancy is planned, and if pregnancy occurs while taking Metformin, it should be cancelled and insulin therapy should be prescribed.

Since there is no data on penetration into breast milk, this drug is contraindicated during breastfeeding.

If Metformip has to be used while breastfeeding, breastfeeding should be stopped.

Similarities